Pharmacology Drug Metabolism and Disposition (ASPET)

Loxoprofen activation favors human intestine, reversed in rats

  • Loxoprofen is a prodrug activated in the liver. Rat studies suggested little GI injury, unlike clinical reports, prompting a human-rat comparison.
  • Intestinal conversion in humans exceeded hepatic conversion, while rats showed the opposite pattern.
  • Human intestinal activity is linked to high expression of the reductases AKR1C3 and CBR1.
  • Rat recombinant reductases were active toward loxoprofen, yet none fully explained tissue activity.
Points Based on the abstract

Can a rat GI-tolerability study be trusted for a prodrug whose activation site flips between species? Probably not here. Human intestinal S9 or organoid data with selective AKR1C3 and CBR1 inhibitors, plus mucosal exposure of the active metabolite, should come before the rat signal is dismissed, since NSAID gut injury also reflects systemic COX inhibition and direct local effects.